Preliminary Efficacy Analysis of 'λ+α' Double-Tract Reconstruction After Laparoscopic Proximal Gastrectomy

Launched by NORTHERN JIANGSU PEOPLE'S HOSPITAL · Jun 20, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new surgical method for patients with early-stage gastric cancer, particularly those with tumors located in the upper part of the stomach. Researchers want to evaluate the safety and effectiveness of a procedure called "λ+α double-channel anastomosis," which aims to help patients recover without suffering from reflux, a condition where stomach acid flows back into the esophagus, causing discomfort. The goal is to improve the quality of life for patients after surgery while effectively treating their cancer.

To participate in this trial, individuals need to be between 18 and 75 years old and have a specific type of gastric cancer that is classified as early-stage. They should not have any distant metastasis (spread of cancer) or certain other health conditions that could complicate surgery. Participants can expect to undergo the new surgical procedure and will be closely monitored for both safety and how well the treatment works. This study is currently seeking volunteers who meet these criteria and are willing to provide informed consent to take part in the research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18-75 years old, male or female; Pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1/3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer： Ia and Ib (T1N0M0, T1N1M0, and T2N0M0) (14) according to the eighth edition of the AJCC (15); No distant metastasis was observed on preoperative chest radiograph, abdominal ultrasound, or upper abdominal CT; ASA grade 1-3; Patients without contraindications to surgery; Patients and their families voluntarily signed the informed consent form and participated in the study;
• Exclusion Criteria:
• • Patients diagnosed with primary tumors or distant metastasis; Patients whose tumor is located in the greater curvature side of the stomach; Patients with coagulation dysfunction that could not be corrected; Patients who were diagnosed with viral hepatitis and cirrhosis; Patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin; Patients with organ failure such as heart, lung, liver, brain, and kidney failure; Patients with ascites or cachexia preoperatively in poor general conditions; Patients diagnosed with immunodeficiency, immunosuppression, or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, SLE, etc.).
• • Patients refusing to sign the informed consent of the study;